参考文献/References:
[1] 尹周一, 王梦圆, 游伟程, 等. 2022 美国癌症统计报 告解读及中美癌症流行情况对比[J]. 肿瘤综合治疗 电子杂志, 2022, 8(2): 54-63. YIN Zhouyi, WANG Mengyuan, YOU Weicheng, et al. Interpretation on the report of American Cancer Statistics, 2022 and comparison of cancer prevalence in China and America[J]. Journal of Multidisciplinary Cancer Management(Electronic Version), 2022, 8(2): 54-63.
[2] 邹小农, 贾漫漫, 王鑫, 等. 《2020 全球癌症报告》 要点解读[J]. 中国胸心血管外科临床杂志, 2021,28(1): 11-18. ZOU Xiaonong, JIA Manman, WANG Xin, et al. Interpretation of the World Cancer Report 2020[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(1): 11-18.
[3] CHEN Xingyu, CHEN Haotian, YAO Honghui,et al. Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer[J]. Oncogene,2021, 40(45): 6381-6393.
[4] 张思佳, 徐彩娜, 陈杰, 等. 通过调控肿瘤代谢增强 T 细胞抗肿瘤活性[J]. 应用化学, 2020, 37(9): 977- 984. ZHANG Sijia, XU Caina, CHEN Jie, et al. Enhancing T cell antitumor activity by regulating tumor metabolism[J]. Chinese Journal of Applied Chemistry,2020, 37(9): 977-984.
[5] 黄柱华, 苏文, 韩正全, 等. 非小细胞肺癌患者的肿 瘤转移与肿瘤浸润的CD8+T 细胞数量负相关[J]. 细 胞与分子免疫学杂志, 2019, 35(3): 266-270. HUANG Zhuhua, SU Wen, HAN Zhengquan, et al. Tumor metastasis in patients with non-small cell lung cancer is inversely correlated with the number of tumor-infiltrating CD8+T cells[J]. Chinese Journal of Cellular and Molecular Immunology, 2019, 35(3): 266- 270.
[6] 李翠霞, 苏秀兰. 长链非编码RNA (LncRNAs) 参 与肿瘤细胞免疫逃逸的研究进展[J]. 免疫学杂志,2019, 35(9): 817-822. LI Cuixia, SU Xiulan. Research progress of long-chain non-coding RNAs (LncRNAs) involved in tumor cell immune escape[J]. Immunological Journal, 2019,35(9): 817-822.
[7] ZHANG Zhengjia, HUANG Qingcai, YU Liuchunyang,et al. The role of miRNA in tumor immune escape and miRNA-based therapeutic strategies[J]. Front Immunol,2021, 12: 807895.
[8] ZHANG Caixiang, WANG Wenying, LIN Jun, et al. LncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion[J]. International Braz J Urol, 2019, 45(3): 549-559.
[9] 李聪聪, 赵金艳, 吴姣, 等. miR-155 研究进展[J]. 生物技术通报, 2018, 34(11): 70-82. LI Congcong, ZHAO Jinyan, WU Jiao, et al. Research progress on miR-155[J]. Biotechnology Bulletin, 2018,34(11): 70-82.
[10] 陈倩云, 范恒. miR-155 调控T 细胞分化与功能的研 究进展[J]. 中国免疫学杂志, 2016, 32(7): 1065-1069. CHEN Qianyun, FAN Heng. Research progress of miR- 155 regulation of T cell differentiation and function[J]. Chinese Journal of Immunology, 2016, 32(7): 1065- 1069.
[11] 白盈盈, 朱光旭, 潘兴华. 长链非编码RNA 对结直 肠癌潜在诊断价值的研究进展[J]. 现代检验医学杂 志, 2018, 33(1): 161-164. BAI Yingying, ZHU Guangxu, PAN Xinghua. Research progress on the potential diagnostic value of long noncoding RNA in colorectal cancer[J]. Journal of Modern Laboratory Medicine, 2018, 33(1): 161-164.
[12] LI J L, LI R, GAO Y, et al. LncRNA CCAT1 promotes the progression of preeclampsia by regulating CDK4[J]. European Review for Medical and Pharmacological Sciences, 2018, 22(5): 1216-1223.
[13] ZHANG Shouhua, XIAO Juhua, CHAI Yong, et al. LncRNA-CCAT1 promotes migration, invasion, and EMT in intrahepatic cholangiocarcinoma through suppressing miR-152[J]. Digestive Diseases and Sciences, 2017, 62(11): 3050-3058.
[14] SUN W, SHEN N M, FU S L. Involvement of LncRNAmediated signaling pathway in the development of cervical cancer[J]. European Review for Medical and Pharmacological Sciences, 2019, 23(9): 3672-3687.
[15] HU Min, ZHANG Qi, TIAN Xiaohui, et al. LncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/ BUBR1 axis[J]. Molecular Carcinogenesis, 2019,58(12): 2207-2217.
[16] L?Li, JIA Jianqin, CHEN Jin. The LncRNA CCAT1 upregulates proliferation and invasion in melanoma cells via suppressing miR-33a[J]. Oncology Research,2018, 26(2): 201-208.
[17] 胡诗芸, 奕天飞, 王家立, 等. 长链非编码RNA 在肿瘤免疫微环境中的作用[J]. 生命科学, 2022,34(2): 212-219. HU Shiyun, YI Tianfei, WANG Jiali, et al. Research progress on long non coding RNA in tumor immune microenvironment[J]. Chinese Bulletin of Life Sciences, 2022, 34(2): 212-219.
[18] YU Jing, JIANG Lijuan, GAO Yutao, et al. LncRNA CCAT1 negatively regulates miR-181a-5p to promote endometrial carcinoma cell proliferation and migration[J]. Experimental and Therapeutic Medicine,2019, 17(5): 4259-4266.
[19] HAN Chunyong, LI Xuebiao, FAN Qian, et al. CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling[J]. Aging, 2019,11(14): 4858-4875.
[20] YOU Zonghao, LIU Chunhui, WANG Can, et al. LncRNA CCAT1 promotes prostate cancer cell proliferation by interacting with DDX5 and miR-28- 5P[J]. Molecular Cancer Therapeutics, 2019, 18(12): 2469-2479.
[21] BAYRAKTAR R, VAN ROOSBROECK K. MiR-155 in cancer drug resistance and as target for miRNAbased therapeutics[J]. Cancer Metastasis Reviews,2018, 37(1): 33-44.
[22] SHAO Chuchu, YANG Fengming, QIN Zhiqiang, et al. The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: A systematic review with meta-analysis[J]. BMC Cancer, 2019, 19(1): 1103.
[23] XIN Xiaoru, LU Yanan, XIE Sijie, et al. MiR-155 accelerates the growth of human liver cancer cells by activating CDK2 via targeting H3F3A[J]. Molecular Therapy Oncolytics, 2020, 17: 471-483.
[24] JI Yun, WRZESINSKI C, YU Zhiya, et al. MiR- 155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines[J]. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(2): 476-481.